Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00222170
Status:
COMPLETED
Last Update Posted:
2009-05-08
First Post:
2005-09-13
Brief Title:
Rabeprazole in Subjects With Gastroesophageal Reflux Disease GERD
Sponsor:
University of Kansas
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Esophagoprotection by Rabeprazole Mediated by Restoration of an Impairment in Esophageal Mucin Production Its Potential Therapeutic Benefit in Patients With Gastroesophageal Reflux Disease GERD
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the production of mucin in GERDRE subjects before and after 8 weeks of treatment with rabeprazole
Detailed Description:
Enrolled patients will undergo collection of salivary and esophageal secretions Subsequently all patients will receive rabeprazole 20mg QD for 8 weeks and will be re-endoscoped to confirm complete healing of reflux esophagitis In patients with completely healed reflux esophagitis the second collection of salivary and esophageal secretion will be implemented In both secretions adequately coded for the laboratory Research Fellow blinded in terms of which sample is collected before and which after treatment with rabeprazole the content of mucin will be measured using commercially available assay and its secretion expressed in units per minute of collection time
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None